Some of the most closely watched results at the American Society of Clinical Oncology (ASCO) meeting this year are those from Chinese firm Shanghai Junshi Biosciences Co., Ltd. and its partner Coherus BioSciences, Inc. for the anti-PD-1 antibody toripalimab in first-line nasopharyngeal carcinoma (NPC).
The read-outs are significant for multiple reasons: it’s a high-need indication with few treatment options; they may lead to a...